πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Theravance Biopharma Ireland Patents

Full USPTO pharma patent portfolio for Theravance Biopharma Ireland β€” grant dates, expiration, and drug cross-links.

Patents
635
Expiring ≀24m
58

Quick answer

Theravance Biopharma Ireland has 635 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 58 expire within 24 months β€” use filters for patent-cliff planning.

Page 3 of 14

  1. US 10494382

    Crystalline solvate comprising 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile, methanol, N-N-dimethylformamide, and water

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10493077

    Fused imidazo-piperidine JAK inhibitor compound

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10485803

    Pyrimidine compounds as JAK kinase inhibitors

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10472335

    Crystalline(2S,4R)-5-(5β€²-chloro-2β€²-fluoro-[1,1β€²-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10472366

    Glucuronide prodrugs of tofacitinib

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10441579

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10435428

    Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10426766

    Crystalline forms of an 8-azabicyclo[3.2.1]octane compound

    Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10406148

    Methods of treatment using a JAK inhibitor compound

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10392368

    Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

    Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10392386

    JAK inhibitors containing a 4-membered heterocyclic amide

    Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10377751

    8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10369142

    Combination dosage form of a mu opioid receptor antagonist and an opioid agent

    Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10358433

    Diamide compounds having muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist activity

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10343995

    Biphenyl compounds useful as muscarinic receptor antagonists

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10336773

    Neprilysin inhibitors

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10315984

    Neprilysin inhibitors

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10308646

    Pyrimidine compound as JAK kinase inhibitor

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10251874

    Crystalline forms of a JAK inhibitor compound

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10238642

    Methods for treating neurogenic orthostatic hypotension

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10233174

    Thiocarbamate prodrugs of tofacitinib

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10233172

    Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10226454

    Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10208040

    Fused imidazo-piperidine JAK inhibitors

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10206913

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10196393

    JAK inhibitors containing a 4-membered heterocyclic amide

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10189823

    Neprilysin inhibitors

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10183942

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10172834

    (2R,4R)-5-(5β€²-chloro-2β€²-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10138220

    Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10130642

    Neprilysin inhibitors

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10123984

    Neprilysin inhibitors

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10106503

    Biphenyl compounds useful as muscarinic receptor antagonists

    Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10100049

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10100021

    Crystalline(2S,4R)-5-(5β€²-chloro-2β€²-fluoro-[1,1β€²-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

    Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10100013

    Crystalline freebase forms of a biphenyl compound

    Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10081626

    8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10072026

    Crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

    Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10053417

    Neprilysin inhibitors

    Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10034870

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10028960

    Pyrimidine compounds as JAK kinase inhibitors

    Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10005740

    Neprilysin inhibitors

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9981999

    Neprilysin inhibitors

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9975875

    Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity

    Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9975877

    Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

    Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9949963

    Crystalline forms of an 8-azabicyclo[3.2.1]octane compound

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9926272

    Biphenyl compounds useful as muscarinic receptor antagonists

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9884807

    Neprilysin inhibitors

    Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Theravance Biopharma Ireland have?

635 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Theravance Biopharma Ireland patents expire?

58 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.